Alexion buys Syntimmune for $400mm plus earn-outs
Alexion Pharmaceuticals Inc. will pay $400mm up front to acquire privately held antibody therapeutics developer Syntimmune Inc. The deal also includes up to $800mm in milestone-dependent earn-outs.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.